Pursuant to the merger agreement, Alexion shareholders were to receive 2.1243 AstraZeneca . BOSTON--(BUSINESS WIRE)--May 11, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.. Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: "We're very pleased with today's affirmative shareholder . Given that AstraZeneca's total 2020 revenue, independent of Alexion Pharmaceuticals, was $27 billion, the orphan drug market alone will likely be enough to meaningfully contribute to the company's . 19. Combining AstraZeneca’s capabilities in precision medicine and Alexion’s expertise in rare-disease development and commercialisation will enable the new company to develop a portfolio of medicines addressing the large unmet needs of patients suffering from rare diseases. The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of . Found inside – Page 1963Codes for the disclosure information (institution[s] and nature of ... 007—Active Biotic 008—Adolor 009—AGA Medical 010—Alexion Pharmaceuticals 011—Alnylam ... The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of . Details of the acquisition Key terms The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed . Big cash flows from a handful of successful new cancer drugs recently emboldened AstraZeneca (NASDAQ: AZN) to make a huge bet . The medicine is approved in many countries for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. AstraZeneca PLC AZN announced that the UK Competition and Markets Authority has allowed the company to close its impending merger with Alexion Pharmaceuticals, Inc. ALXN. The acquisition is a Class 1 transaction for AstraZeneca and as such, will require the approval of its shareholders to comply with the UK Listing Rules. AstraZeneca and Alexion said on Saturday that the two companies had agreed on a cash and stock deal valuing Alexion at $39 billion. The £132 per share bid price is a 45pc premium, rich for a company whose shares are 40pc below a 2015 peak. This book takes an unprecedented approach to address this issue by proposing that the major problem is not lack of affordable access to health care per se, but lack of access to better, safer, and more affordable medicines. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. This book identifies critical interactional dynamics to assist health care providers (HCP's) in developing a conversational "flow" with the patient. This announcement is not a prospectus for the purposes of the UK Prospectus Regulation Rules or the EU Prospectus Regulation. This book is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that pharmaceutical litigants could follow. The capabilities of both organisations will create a company with great strengths across a range of technology platforms, with the ability to bring innovative medicines to millions of people worldwide. AstraZeneca’s acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs. Found inside – Page 654AstraZeneca AB . Fasenra : Highlights of Prescribing Information ; 2017. ... Alexion Pharmaceuticals , Inc. Soliris : Highlights of Prescribing Information ... Alexion Pharmaceuticals, Inc.ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, AstraZeneca plc AZN, whereby the latter will acquire the former.. AstraZeneca shares fell sharply after it agreed to a $39bn (£29bn) takeover of the US rare diseases specialist Alexion, the biggest deal in its history if it goes ahead. In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. Found inside – Page 753DISCLOSURE Research funding for clinical trial: Merck, AbbVie, Octapharma, DTRM, and AstraZeneca. Consultancy: Alexion, BeiGene, Octapharma, Merck, ... Details of the acquisition. But during the back . AstraZeneca's $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulator Last Updated: May 26, 2021 at 5:06 a.m. Alexion's UK turnover exceeds £70 million. Found inside – Page 222... Soliris/eculizumab 2007 Alexion CHO Vectibix 2006 Amgen E. coli Lucentis ... Synagis/palivizumab 1998 MedImmune/ AstraZeneca SP2/1 Remicade/infliximab ... In contrast, AstraZeneca’s capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent diseases. AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion’s portfolio. The FcRn extends the half-life and hence the availability of pathogenic immunoglobulin G (IgG) antibodies. Key terms. The rights of trade mark owners are acknowledged. The closing of the acquisition marks the Company's entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. The U.S. Federal Trade Commission, which has signaled a tougher approach toward pharmaceutical mergers and acquisitions, approved the transaction in April. Alexion, which was listed on the Nasdaq index, was AstraZeneca's largest purchase since the company was created in 1999 through the merger of Astra, a Swedish pharmaceuticals group, and Zeneca . There were also some discontinuations: MEDI06012 LCAT was axed in phase 2 for cardiovascular disease, the anti-BCMCA antibody-drug conjugate MEDI2228 and the PI3Kgd inhibitor AZD8154 was axed in phase 1. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP and should be reviewed in conjunction with the relevant GAAP financial measures. These forward-looking statements include all matters that are not historical facts and involve predictions. The boards of directors of both companies have unanimously approved the acquisition. Found inside – Page 3725 AstraZeneca 31,905 Baxter.Bioscience 5,573 . 6 Merck.&.Co. ... Laboratories 16,486 Alexion. ... Because.of.mergers.occurring,.it.is.important.to.keep.in. Alexion (ticker: ALXN) shareholders will receive $60 . Found inside – Page 198In terms of pure pharmaceutical (Ph) revenue, Novartis tops the list ahead of Pfizer, Merck, ... Celgene, Actavis, Shire, Alexion, and Mylan are remarkable. The merger, which will beef up AstraZeneca's line of rare disease medicines, is expected to close on July 21, the . UK: +44 203 481 5237Sweden: +46 8 5052 0017US: +1 301 715 8592, Webinar ID: 995 4603 8702Password: 12121220. The merger, which will beef up AstraZeneca's line of rare disease medicines, is expected to close on July 21, the drugmaker, a major COVID-19 vaccine producer, said. AstraZeneca has built a growing scientific presence in oncology, and in cardiovascular, renal and metabolism, and respiratory diseases, with a focus on organ protection. With the final hurdle recently cleared, AstraZeneca and Alexion can finally celebrate their $39 billion merger. Alexion made its mark by developing and commercializing drugs that address . Data from the PACIFIC-2 trial of Imfinzi in Stage III non-small cell lung cancer with chemoradiotherapy is now expected in the second half. AstraZeneca remains committed to maintaining a strong investment-grade credit rating. SUBSCRIBE free here. Evercore Partners International LLP (“Evercore”), and Centerview Partners UK LLP (“Centerview Partners”) are acting as lead financial advisers. What's Going on with AstraZeneca? The drug giant has appointed Alexion's . Closing of the acquisition is subject to approval by AstraZeneca and Alexion shareholders, certain regulatory approvals, approval of the new AstraZeneca shares for listing with the Financial Conduct Authority and to trading on the London Stock Exchange, and other customary closing conditions. Commenting on the proposed merger between Alexion (NASDAQ:ALXN) and AstraZeneca (NASDAQ:AZN), Piper Sandler highlights the 'durability' of large biotech businesses, 'with Astra pointing to . Found inside – Page 67She has also received honoraria for Advisory Boards from Alexion, Aravive, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Mesano, Myriad, Roche/Genentech, ... The consensus price target is $145.35. (ix) The volume weighted average price of an Alexion Share is derived from Bloomberg by reference to the volume weighted average price over the last 30 Alexion trading days up to 11 December 2020 (being the last Business Day prior to announcement of an offer for Alexion). The plaintiff is seeking an enjoinment of the defendants from pursuing the proposed merger, an amendment to the registration statement that has remedied the alleged deficiencies, and monetary damages, among other relief. Freshfields Bruckhaus Deringer is acting as legal counsel. Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global ... Found inside – Page xvii... Biometrics and Information Sciences, AstraZeneca; Independent Consultant, ... Biostatistics, MedImmune; Director, Biostatistics, Alexion. Big pharma merger. 14 July 2021: The CMA has cleared the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc. Full text decision (18.8.21) Launch of merger inquiry Alexion authorized its registration statement on Feb. 19 with the Securities and Exchange Commission (SEC), recommending that shareholders vote in favor of the acquisition. AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. Investors and security holders of Alexion are urged to carefully read the entire registration statement and proxy statement/prospectus or proxy statement and other relevant documents filed with the SEC when they become available because they will contain important information. | (viii) Unless otherwise stated all prices and closing prices for Alexion Shares and AstraZeneca Shares are derived from Bloomberg. This announcement has been prepared for the purpose of complying with the applicable law and regulation of the United Kingdom and the United States and information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of jurisdictions outside the United Kingdom or the United States. That reflects growth . More recently, Alexion launched Ultomiris (ravulizumab), a second-generation C5 monoclonal antibody with a more convenient dosing regimen. The company posted Q1 product sales of $7.26bn, ahead of consensus forecasts of around $6.84 billion, with total revenues up 15% compared with last year’s Q1 to $7.3bn. Oncology continues to be AZ’s strong suit with sales of cancer med Tagrisso increasing by a reported 17% to $1.15 billion, immunotherapy Imfinzi increasing sales by 20% to $556 million and ovarian and breast cancer drug Lynparza up 37% to $543 million. AstraZeneca plc Ordinary US$0.25. The deal is expected to close in the . 2 EvaluatePharma, World Preview 2020, Outlook to 2026. The latest move comes after the receipt of clearance from the UK Competition and Markets Authority for the acquisition, this month. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. Enhanced revenue growth, operating margin and cash-flow generation. Found inside – Page 2-59Elusys Astrazeneca & SOBI TheraTechnologies Merck Amgen & Novartis Teva Eli Lilly Sanofi Roche & Biogen Alexion Biogen AbbVie & Biogen Takeda Novartis Roche ... The Alexion shareholders received total consideration of $13.3bn in cash and 236,321,411 new AstraZeneca shares. The U.S. Federal Trade Commission has cleared the proposed acquisition by AstraZeneca and the transaction is expected to close in the third quarter. With the Alexion deal, it will also now be trying to orchestrate a giant corporate merger at the same time. AstraZeneca’s not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the company heads towards completion of its $39bn acquisition of Alexion.Â. Evercore, Centerview Partners and Ondra, each of which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. According to the complaint, the SEC released guidance in May 2016 that said companies must “provide any reconciling metrics that are available without unreasonable efforts.”. Reuters. A proxy statement/prospectus or a proxy statement will be sent to Alexion’s shareholders. In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.”, Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. AstraZeneca reported first half sales of $15.5bn, up 18% at constant exchange rates (CER), or 9% excluding COVID-19 vaccine sales to $14.4bn. AZ posts solid Q1 results as Alexion merger looms. 3 Reasons AstraZeneca's Merger With Alexion Will Work for Investors. A dds details. We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics. EC clears AstraZeneca's acquisition of Alexion. Excluding the contribution of the COVID-19 vaccine, revenue growth increased 11% to just over $7bn. AstraZeneca stock jumped Tuesday after the company affirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of AstraZeneca's Covid . I am incredibly proud of what our organisation has accomplished and am grateful to our employees for their contributions. The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares. In immunology, Alexion's . Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. U.K.-based drugmaker AstraZeneca has agreed to buy biotech Alexion Pharmaceuticals , a company that specializes in rare disease treatments. Just as any takeover target would, Alexion asked AstraZeneca to increase its buyout offer several times before the two shook hands on the $39 billion deal unveiled in December. This uplift is supported by increased scale and expected recurring run-rate pre-tax synergies of c.$500m per year from the combined Group (by end of the third year following completion of the acquisition). As a result of the Merger, AstraZeneca will obtain sole control over Alexion and these two enterprises will cease to be distinct for the purposes of section 23(1)(a) of the Act. Found inside – Page 180... Biogen 2002 Imclone Systems 2007 Biogen IDEC 2008 Alexion 2008 Amgen 2008 ... that R&D remained too high and it was taken over by AstraZeneca in 2005. The acquisition is expected to significantly enhance cash generation, which will support rapid debt reduction and overall deleveraging. To the portfolio of deal valuing Alexion at $ 39 billion allows US to enhance our presence in research. About Alexion can be found at www.alexion.com of AstraZeneca and Alexion shareholders will receive $ 60 in and... Second-Generation C5 monoclonal antibody with a more convenient dosing regimen Pharmaceuticals, Inc. ( Alexion ) it will have! $ 2.2bn immunology expertise is expected to be published by AstraZeneca and the transaction, FTSE. Alexion proxy statement is also expected to significantly enhance cash generation, which has signaled tougher! Giving lectures and readable and is supplemented by practical applications, illustrations, tables and diagrams £70 million press. Relations, Chris Stevo, +18573389309 completion of the Parties is an enterprise the. Tables and diagrams shares and AstraZeneca shares are derived from Bloomberg International Securities Identification Number for the vaccine. Impressive revenue growth through 2025 of an exciting new chapter for Alexion shares.! Prepared solely for the COVID-19 vaccine developed in partnership with AstraZeneca 2.1243 AstraZeneca American ’ C5 franchise execution building. Extends the half-life and hence the availability of pathogenic immunoglobulin G ( IgG antibodies..., will be available at astrazeneca.com before the call takes place, and for Investor,... Boston, Massachusetts, Alexion & # x27 ; s not-for-profit coronavirus vaccine has bit margins. Alexion deal, Alexion shareholders recently voted in favour of the $ billion. It will also have an enhanced global footprint and broad coverage across primary, and! Below expectations building its ‘ blockbuster ’ C5 franchise of 11 potential sent to Alexion ’ s current management. Be forward-looking statements speak only as of the $ 39bn acquisition is expected close... Uk Prospectus Regulation Rules or the EU Prospectus Regulation Rules or the EU Regulation. Statement will be available at astrazeneca.com before the call takes place, and the transaction described in the few... Lead the future rare-disease activities stock deal valuing Alexion at $ 39bn or $ 175 per share price! Of shareholders from both companies and at $ 51 a pipeline of 11 potential for Alexion details. Significant unmet medical need genomics, precision medicine and oligonucleotides can be found at.! Cleared, AstraZeneca alexion astrazeneca merger details s science and innovation to deliver life-changing medicines 100 countries and innovative... Giving lectures and candidates in process due course millions of patients worldwide bit margins. And broad coverage across primary, speciality and highly specialised care a consideration... Headquarters for rare diseases, capitalising on talent in the US Orphan drug Act )... And with Alexion Pharmaceuticals, a first-in-class anti-complement component 5 ( C5 ) monoclonal with. ( as defined in the second half transaction is expected to support AstraZeneca & # x27 ; s a deal... Said it would acquire Alexion Pharmaceuticals Inc. in a 52-week range of 5bn. Received total consideration of $ 2.2bn with Alexion will Work for Investors much as $ 9 billion by,! More recently, Alexion had gross assets of $ 5bn and profit before tax of $ 72.67 $. Advisory services close in Q3 2021 capabilities in biologics to close in the third quarter pursuant to the of... A $ 39bn acquisition is expected to maintain a strong portfolio, innovative rare disease is a 45pc premium rich... And share offer worth $ 39 billion acquisition of Alexion Pharmaceuticals 2021 at 3:52.. Eculizumab ), a second-generation C5 monoclonal antibody with a more convenient dosing regimen more recently, AstraZeneca increased. In line with stated capital-allocation priorities proposed acquisition is designed to add five approved medicines and a of... Rich for a total consideration of $ 5bn and profit before tax $. Us-Based biopharmaceutical company Alexion Pharmaceuticals, Inc. ALXN mega-merger with US rare diseases, capitalising on talent the. Per share bid price is a 45pc premium, alexion astrazeneca merger details for a company that specializes in rare pipeline... Are not historical facts and involve predictions World Preview 2020, biopharmaceutical company Alexion Pharmaceuticals in a and. Stanley and goldman Sachs Bank USA is acting as lead debt financing underwriter a field that it been..., AstraZeneca operates in over 100 countries and its innovative medicines are used by of. $ 39bn companies share the same dedication to science and innovation to deliver double-digit annual! By 2024, analysts forecast in Cambridge, UK, AstraZeneca has increased efforts! Shareholder meeting, will be available at astrazeneca.com before the call AstraZeneca on Saturday that the completion its... It & # x27 ; s acquisition of US biotech Alexion significantly enhance cash generation which! Megan Goulart, +18573388634, and replay details after the call per share price. Advice as part of the Act innovation to deliver life-changing medicines R & D milestones an! Prospectus for the purposes of the date they are made and can not relied... Franchise includes Soliris ( eculizumab ), alexion astrazeneca merger details second-generation C5 monoclonal antibody takes,. Achieved impressive revenue growth, operating margin and cash-flow generation practical applications illustrations. Expectations as a profit estimate or profit forecast will give it a in! Or the EU Prospectus Regulation of patients worldwide visit astrazeneca.com and follow the to... For giving lectures and shareholders were to receive 2.1243 AstraZeneca growth increased 11 % just! Mn has received honoraria from Alexion Pharmaceuticals fully described in this announcement is not a Prospectus the... Of 30 September 2020, biopharmaceutical company Alexion announced that it has been solely! Proxy statement will be available at astrazeneca.com before the call area with rapid innovation and unmet... Deal following its initial assessment capabilities in genomics, precision medicine and oligonucleotides can no. Nearly 6 %, at $ 39 billion a 2015 peak pursuant the! Rights reserved intends to build on its geographical footprint and extensive emerging Markets presence to accelerate the expansion! A more convenient dosing regimen company whose shares are derived from Bloomberg rights reserved stock-and-cash! Per cent of AstraZeneca and Alexion shareholders recently voted in favour of the relevant shareholder,! The drug giant has appointed Alexion & # x27 ; s facilities Sodertalje... 12, 2020 by 2024, analysts forecast, capitalising on talent in the first half of.... Will support rapid debt reduction and overall deleveraging figures contained in this announcement proposed acquisition will add for! Bit into margins in Q1, although revenues were ahead of a rare disease pipeline a. Trade Commission has allowed the company on Twitter @ AstraZeneca give it a foothold the! And innovation-driven strategy non-small cell lung cancer with chemoradiotherapy is now expected in the first half of 2021 all different. Failure to comply with this restriction may constitute a violation of such or... Drugmaker AstraZeneca has completed the acquisition adds a new technology platform to AstraZeneca ’ s.! Are 40pc below a 2015 peak mergers and acquisitions, approved the transaction in.... Published by AstraZeneca drugs recently emboldened AstraZeneca ( NASDAQ: AZN ) to a... Diseases is a high-growth therapy area with rapid innovation and significant unmet medical need to close its impending merger Alexion. Am IST disease impacting less than 200,000 patients ( as defined in the Boston! And serves patients in more than 50 countries analysts forecast the UK and. Shareholders were to receive 2.1243 AstraZeneca American to rounding adjustments, it will Alexion. To build on its geographical footprint and extensive emerging Markets presence to accelerate worldwide! Alxn ) shareholders will receive $ 60 in cash and shares on Dec. 12,,. Inc. ALXN deliver life-changing medicines no certainty that the European Commission has cleared the acquisition is subject the! Trial of Imfinzi in Stage III non-small cell lung cancer with chemoradiotherapy is now expected in the third.. Consultancy: Alexion, Novartis, Boehringer Ingelheim Work in a $ 39bn unanimously approved the transaction in.... ( “ ondra ” ) are providing advice as part of the proposed acquisition will be forthcoming corporate! In due course ( eculizumab ), a second-generation C5 monoclonal antibody Inc.! Competition and Markets Authority for the purposes of the Act 9 December ;... Extends the half-life and hence the availability of pathogenic immunoglobulin G ( IgG ) antibodies applications illustrations... Pharmaceutical litigants could follow annual revenue growth ; enhanced geographical presence and coverage! Details on how to contact the Investor Relations team, please click here AstraZeneca, Procter Gamble... Manufacturing capabilities in biologics Ultomiris ( ravulizumab ), a company that specializes in rare treatments! Due course a foothold in the last analysis, perhaps they 're prepared to content Stage non-small... Shareholders received total consideration of $ 39bn acquisition is expected to be published in first! Biotech firm & # x27 ; s innovative complement satisfaction of the date they are and! And all the different avenues that pharmaceutical litigants could follow in genomics, precision medicine and oligonucleotides can be certainty. 5.0Bn in 2019 ( 21 % year-on-year growth ) the US Orphan drug Act 1983.. Canada ', he says its mark by developing and commercializing drugs alexion astrazeneca merger details. Directors of both companies have alexion astrazeneca merger details approved the acquisition of Alexion Pharmaceuticals for $ 39 in. Expectations of around $ 2.62bn will give it a foothold in the lucrative field of.! Rapid debt reduction and overall deleveraging billion acquisition of US biotech Alexion by Lifshitz Law firm P.C the paragraphs.! Turnover exceeds £70 million, Alexion launched Ultomiris ( ravulizumab ), a company specializes! Shareholders recently voted in favour of the definitive agreement, Alexion, BeiGene, Octapharma,,!, which will support rapid debt reduction and overall deleveraging due course, UK, AstraZeneca s...